- Galderma's sales of Metvix increased by 57 % to 5738 units (3658) in the third quarter. Nordic Metvix sales increased by 20 % to 2766 units (2298).
- First commercial sales of Hexvix in the Nordic region.
- Hexvix recommended in European guidelines for diagnosis of bladder cancer (carcinoma in situ, CIS).
- Following promising results in proof-of-concept study, development of product for treatment of acne initiated.
- Metvix approved in Brazil.
- Sales and milestone revenues in the third quarter totalled NOK 11.2 million (37.4). Net loss NOK -4.8 million (13.9). Earnings per share NOK -0.28 (NOK 0.79)
- Liquid funds at 30 September 2005 amounted to NOK 81 million.
President and CEO of PhotoCure, Kjetil Hestdal comments: "We are pleased to see that the Metvix sales continue to grow in all markets. Furthermore, the new European guidelines for diagnosis of CIS in the bladder reflect the positive response that Hexvix has received among urologists and is an important recognition of our new product by the European Association of Urology. "
The full report and the presentation of the third quarter of 2005 are available on www.photocure.com (see: /Investors/Reports and Presentations).
The report is also available at the following link:
The presentation is available at the following link:
For further information, please contact:
President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535
Office: +47 22 06 22 10
CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938
Office: +47 22 06 22 10
PhotoCure ASA is a Norwegian pharmaceutical company listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets.
PhotoCure has two products with sales and marketing approvals: Metvix®, for the treatment of skin cancer (basal cell carcinoma) and pre-cancerous skin lesions (actinic keratosis), and Hexvix®, for the detection of bladder cancer. Both products are based on the same photodynamic technology, combining the drug known as a photosensitiser with a light source that activates the photosensitiser. PhotoCure is currently testing both products for new indications and aims to develop a pipeline of follow-on products and technologies.
